Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia

Psychiatry Research - Neuroimaging

Volumn 233, Issue 2, 2015, Pages 186-193

  Emsley, Robin ^a   Asmal, Laila ^a   Chiliza, Bonginkosi ^a   du Plessis, Stefan ^a   Carr, Jonathan ^a   Kidd, Martin ^b   Malhotra, Anil K ^c   Vink, Matthijs ^d   Kahn, Rene S ^d  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPENTIXOL DECANOATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; RISPERIDONE; TRIACYLGLYCEROL; DELAYED RELEASE FORMULATION; FLUPENTIXOL;

ADULT; ARTICLE; BODY MASS; BRAIN REGION; BRAIN SIZE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DIENCEPHALON; FEMALE; FIRST EPISODE SCHIZOPHRENIA; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GRAY MATTER; HUMAN; LOADING DRUG DOSE; MALE; METABOLISM; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VENTRAL DIENCEPHALON; YOUNG ADULT; ADOLESCENT; ANALOGS AND DERIVATIVES; BRAIN; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EATING; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; BRAIN; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; EATING; FEMALE; FLUPENTHIXOL; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INJECTIONS, INTRAMUSCULAR; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; SOUTH AFRICA; YOUNG ADULT;

EID: 84938739681     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2015.06.014     Document Type: Article

References (44)

1. Andreasen N.C., Liu D., Ziebell S., Vora A., Ho B.C. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am. J. Psychiatry 2013, 170:609-615.
2. Andreasen N.C., Nopoulos P., Magnotta V., Pierson R., Ziebell S., Ho B.C. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol. Psychiatry 2011, 70:672-679.
3. Araujo E.P., Torsoni M.A., Velloso L.A. Hypothalamic inflammation and obesity. Vitamins Hormones 2010, 82:129-143.
4. Ascher-Svanum H., Stensland M.D., Kinon B.J., Tollefson G.D. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J. Psychopharmacol. 2005, 19:110-117.
5. Berthoud H.R., Morrison C. The brain, appetite, and obesity. Ann. Rev. Psychol. 2008, 59:55-92.
6. Boghi A., Sterpone S., Sales S., D'Agata F., Bradac G.B., Zullo G., Munno D. In vivo evidence of global and focal brain alterations in anorexia nervosa. Psychiatry Res. 2011, 192(3):154-159. 30.
7. Brooks S.J., Benedict C., Burgos J., Kempton M.J., Kullberg J., Nordenskjold R., Kilander L., Nylander R., Larsson E.M., Johansson L., Ahlstrom H., Lind L., Schioth H.B. Late-life obesity is associated with smaller global and regional gray matter volumes: a voxel-based morphometric study. Int. J. Obesity (London) 2013, 37:230-236.
8. Canfran-Duque A., Casado M.E., Pastor O., Sanchez-Wandelmer J., de la Pena G., Lerma M., Mariscal P., Bracher F., Lasuncion M.A., Busto R. Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J. Lipid Res. 2013, 54:310-324.
9. Coppari R. Metabolic actions of hypothalamic SIRT1. Trends Endocrinol. Metabolism 2012, 23:179-185.
10. Dale A.M., Fischl B., Sereno M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999, 9:179-194.
11. De Silva S.A., Salem V., Matthews P.M., Dhillo W.S. The use of functional MRI to study appetite control in the CNS. Experimental. Diabetes Res. 2012, 2012:764017.
12. Fischl B., Sereno M.I., Dale A.M. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage. 1999, 9:195-207.
13. Foley D.L., Morley K.I. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch. Gen. Psychiatry 2011, 68:609-616.
14. Fusar-Poli P., Smieskova R., Kempton M.J., Ho B.C., Andreasen N.C., Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci. Biobehav. Rev. 2013, 37:1680-1691.
15. Girgis R.R., Diwadkar V.A., Nutche J.J., Sweeney J.A., Keshavan M.S., Hardan A.Y. Risperidone in first-episode psychosis: a longitudinal, exploratory voxel-based morphometric study. Schizophr. Res. 2006, 82:89-94.
16. Glenthoj A., Glenthoj B.Y., Mackeprang T., Pagsberg A.K., Hemmingsen R.P., Jernigan T.L., Baare W.F. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res. 2007, 154:199-208.
17. Goghari V.M., Smith G.N., Honer W.G., Kopala L.C., Thornton A.E., Su W., MacEwan G.W., Lang D.J. Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naive first-episode psychosis patients. Schizophr. Res. 2013, 149:149-155.
18. Ha J., Cohen J.I., Tirsi A., Convit A. Association of obesity-mediated insulin resistance and hypothalamic volumes: possible sex differences. Dis. Markers 2013, 35:249-259.
19. Haijma S.V., Van H.N., Cahn W., Koolschijn P.C., Hulshoff Pol H.E., Kahn R.S. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr. Bull. 2013, 39:1129-1138.
20. He M., Deng C., Huang X.F. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 2013, 27:423-434.
21. Ho B.C., Andreasen N.C., Ziebell S., Pierson R., Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011, 68:128-137.
22. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E., EUFESTstudy group Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371(9618):1085-1097. 29.
23. Kay S.R., Fizbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr. Bull. 1987, 13:261-267.
24. Kurth F., Levitt J.G., Phillips O.R., Luders E., Woods R.P., Mazziotta J.C., Toga A.W., Narr K.L. Relationships between gray matter, body mass index, and waist circumference in healthy adults. Hum. Brain Map. 2013, 34:1737-1746.
25. Li M., Chen Z., Deng W., He Z., Wang Q., Jiang L., Ma X., Wang Y., Chua S.E., Cheung C., McAlonan G.M., Sham P.C., Collier D.A., Gong Q., Li T. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment. Psychol. Med. 2012, 42:1475-1483.
26. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., Bilder R. Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatry 2001, 49:487-499.
27. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 2005, 62:361-370.
28. Malhotra A.K., Correll C.U., Chowdhury N.I., Muller D.J., Gregersen P.K., Lee A.T., Tiwari A.K., Kane J.M., Fleischhacker W.W., Kahn R.S., Ophoff R.A., Meltzer H.Y., Lencz T., Kennedy J.L. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch. Gen. Psychiatry 2012, 69:904-912.
29. Marques-Iturria I., Pueyo R., Garolera M., Segura B., Junque C., Garcia-Garcia I., Jose Sender-Palacios M., Vernet-Vernet M., Narberhaus A., Ariza M., Jurado M.A. Frontal cortical thinning and subcortical volume reductions in early adulthood obesity. Psychiatry Res. 2013, 214:109-115.
30. Massana G., Salgado-Pineda P., Junque C., Perez M., Baeza I., Pons A., Massana J., Navarro V., Blanch J., Morer A., Mercader J.M., Bernardo M. Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. J. Clin. Psychopharmacol. 2005, 25:111-117.
31. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott S.T., Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80:19-32.
32. Olabi B., Ellison-Wright I., McIntosh A.M., Wood S.J., Bullmore E., Lawrie S.M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol. Psychiatry 2011, 70:88-96.
33. Polymeropoulos M.H., Licamele L., Volpi S., Mack K., Mitkus S.N., Carstea E.D., Getoor L., Thompson A., Lavedan C. Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. Schizophr. Res. 2009, 108:134-142.
34. Reuter M., Rosas H.D., Fischl B. Highly accurate inverse consistent registration: a robust approach. Neuroimage 2010, 53:1181-1196.
35. Reuter M., Schmansky N.J., Rosas H.D., Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012, 61:1402-1418.
36. Shisana, O., Labadarios, D., Rehle, T., Simbayi, L., Zuma, K., Dhansay, A., Reddy, P., Parker, W., Hoosain, E., Naidoo, P., Hongoro, C., Mchiza, Z., Steyn, N.P., Dwane, N., Makoae, M., Maluleke, T., Ramlagan, S., Zungu, N., Evans, M.G., Jacobs, L., Faber, M., 2014. The SANHANES-1 Team (2014) South African National Health and Nutrition Examination Survey (SANHANES-1): 2014 Edition. Cape Town: HSRC Press.
37. Stip E., Lungu O.V., Anselmo K., Letourneau G., Mendrek A., Stip B., Lipp O., Lalonde P., Bentaleb L.A. Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl. Psychiatry 2012, e128. 10.1038/tp.2012.53.
38. Szeszko P.R., Robinson D.G., Ikuta T., Peters B.D., Gallego J.A., Kane J., Malhotra A.K. White matter changes associated with antipsychotic treatment in first-episode psychosis. Neuropsychopharmacology 2014.
39. Taki Y., Kinomura S., Sato K., Inoue K., Goto R., Okada K., Uchida S., Kawashima R., Fukuda H. Relationship between body mass index and gray matter volume in 1428 healthy individuals. Obesity (Silver Spring) 2008, 16:119-124.
40. Tarricone I., Ferrari G.B., Serretti A., Grieco D., Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol. Med. 2010, 40:187-200.
41. Thaler J.P., Schwartz M.W. Minireview: Inflammation and obesity pathogenesis: the hypothalamus heats up. Endocrinology 2010, 151:4109-4115.
42. Vachharajani V., Granger D.N. Adipose tissue: a motor for the inflammation associated with obesity. IUBMB Life 2009, 61:424-430.
43. Walther K., Birdsill A.C., Glisky E.L., Ryan L. Structural brain differences and cognitive functioning related to body mass index in older females. Hum. Brain Map. 2010, 31:1052-1064.
44. Zipursky R.B., Reilly T.J., Murray R.M. The myth of schizophrenia as a progressive brain disease. Schizophr. Bull. 2013, 39:1363-1372.